<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Refractoriness to platelet transfusion
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Refractoriness to platelet transfusion
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Refractoriness to platelet transfusion
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard Max Kaufman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Steven Kleinman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer S Tirnauer, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 12, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         This topic discusses the causes, evaluation, and management of refractoriness to platelet transfusion, as defined below.
        </p>
        <p>
         Separate topics discuss:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General principles of platelet transfusion
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/7918.html" rel="external">
          "Platelet transfusion: Indications, ordering, and associated risks"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation of thrombocytopenia
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Child
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/5939.html" rel="external">
          "Approach to the child with unexplained thrombocytopenia"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Adult
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/6680.html" rel="external">
          "Diagnostic approach to thrombocytopenia in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drug-induced thrombocytopenia
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/6674.html" rel="external">
          "Drug-induced immune thrombocytopenia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3966376943">
         <span class="h1">
          DEFINITION AND PREVALENCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Platelet refractoriness refers to a suboptimal response to platelet transfusions (smaller than expected platelet count increment after transfusion) on more than one occasion [
         <a href="#rid1">
          1
         </a>
         ]. In routine clinical practice, failure to observe a post-transfusion platelet increment of at least 10,000/microL is considered suspicious for refractoriness [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         To improve the consistency of reporting in research studies, it is standard to adjust the absolute platelet increment to account for the number of platelets transfused and the size of the transfusion recipient. The corrected count increment (CCI) is the most used such metric. (See
         <a class="local">
          'CCI'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The 1997 TRAP trial, which evaluated the role of leukoreduction (post-storage) in preventing platelet refractoriness (see
         <a class="local">
          'Prevention'
         </a>
         below), defined platelet refractoriness as a CCI &lt;5000/microL after two sequential transfusions of ABO-compatible platelets [
         <a href="#rid3">
          3,4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 2018 guideline from American Society of Clinical Oncology (ASCO) on platelet transfusion in patients with cancer endorsed the definition of platelet refractoriness as a CCI &lt;5000/microL following at least two ABO-compatible platelet transfusions using platelets stored &lt;72 hours, but the guideline emphasized that evidence is weak, inter-individual variation occurs, and this criterion should not take the place of physician judgment [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The incidence of platelet refractoriness depends on the population, with a higher likelihood in individuals who are seriously ill, heavily transfused, or both. In the PLADO trial, which evaluated platelet dosing strategies in individuals with thrombocytopenia due to chemotherapy or hematopoietic stem cell transplant (HSCT), 102 of 734 patients who received at least two platelet transfusions (14 percent) developed platelet refractoriness by the TRAP definition [
         <a href="#rid6">
          6
         </a>
         ]. Alloimmunization occurred in 40 of 816 evaluable participants (5 percent). Observational studies have reported platelet refractoriness in 13 to 44 percent of participants [
         <a href="#rid2">
          2,6-10
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H16695439">
         <span class="h1">
          FACTORS ASSOCIATED WITH PLATELET REFRACTORINESS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Refractoriness to platelet transfusion is often multifactorial.
        </p>
        <p>
         The causes are generally divided into non-immune and immune  (
         <a class="graphic graphic_table graphicRef67416" href="/z/d/graphic/67416.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ]. Most cases are non-immune [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         Contribution of both non-immune causes and alloimmunization is especially likely in individuals who have been pregnant, and in heavily transfused individuals, such as people with hematologic malignancies or after HSCT. These individuals may have infection or chemotherapy-induced thrombocytopenia causing reduced platelet lifespan plus anti-human leukocyte antigen (anti-HLA) alloantibodies causing alloimmune refractoriness.
        </p>
        <p class="headingAnchor" id="H16695446">
         <span class="h2">
          Non-immune causes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Non-immune causes account for most episodes of platelet refractoriness. These include conditions associated with rapid platelet consumption or sequestration from the circulating blood volume. Transfused platelets can be consumed or sequestered so rapidly that the platelet count one hour after transfusion fails to increase substantially, but usually with non-immune causes the platelet count increment is higher at 10 minutes to 1 hour and lower at 24 hours. (See
         <a class="local">
          'Determining the cause'
         </a>
         below.)
        </p>
        <p>
         Common examples include [
         <a href="#rid11">
          11
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sepsis, infection, or fever
         </strong>
         – Fever and infections have been associated with reduced platelet increments [
         <a href="#rid2">
          2
         </a>
         ]. It is unclear whether fever is a marker of severe infection rather than an independent risk factor for platelet refractoriness [
         <a href="#rid12">
          12,13
         </a>
         ]. Platelet interactions with bacteria, neutrophils, and activated endothelial cells may also contribute to reduced platelet survival [
         <a href="#rid11">
          11
         </a>
         ]. Sepsis may be accompanied by other platelet consumptive processes such as disseminated intravascular coagulation (DIC) or hemophagocytosis [
         <a href="#rid14">
          14-16
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1306.html" rel="external">
          "Evaluation and management of disseminated intravascular coagulation (DIC) in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Splenomegaly
         </strong>
         – Platelets pool in the spleen, and splenomegaly is well established as a cause of reduced platelet count increments following platelet transfusion. Under normal conditions, approximately one-third of an individual's platelets are sequestered in the spleen, where they are in equilibrium with the circulating platelet pool. In cases of extreme splenomegaly, splenic sequestration can be increased to 90 percent  (
         <a class="graphic graphic_figure graphicRef52400" href="/z/d/graphic/52400.html" rel="external">
          figure 1
         </a>
         ). It can be expected that a large fraction of the transfused platelets will be sequestered in an enlarged spleen [
         <a href="#rid17">
          17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7134.html" rel="external">
          "Splenomegaly and other splenic disorders in adults", section on 'Hypersplenism'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a study of platelet responses in individuals with bone marrow suppression (mostly leukemia), prior splenectomy correlated with a greater platelet count increment, further supporting the idea that an enlarged spleen would lower the increment [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          DIC
         </strong>
         – DIC results in an increased rate of platelet consumption and refractoriness to platelet transfusion. This is a particular problem in cases of acute promyelocytic leukemia where DIC may result in an increased risk of fatal hemorrhage [
         <a href="#rid18">
          18
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1306.html" rel="external">
          "Evaluation and management of disseminated intravascular coagulation (DIC) in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4527.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults", section on 'Coagulopathy and APL'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bleeding
         </strong>
         – Bleeding is considered an independent risk factor for reduced platelet increment [
         <a href="#rid2">
          2
         </a>
         ]. Presumably the mechanism involves platelet loss and consumption.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Medications
         </strong>
         – Numerous medications can cause drug-induced thrombocytopenia, by a variety of immune and non-immune mechanisms. Heparin and amphotericin are two notable examples. Details and lists of implicated drugs are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/6674.html" rel="external">
          "Drug-induced immune thrombocytopenia", section on 'List of drugs'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HSCT
         </strong>
         – Additional non-immune causes in individuals who have undergone HSCT may include hepatic sinusoidal obstruction syndrome (hepatic veno-occlusive disease [VOD]) and graft-versus-host disease (GVHD), although not all studies have documented these associations [
         <a href="#rid2">
          2,8,12,19,20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H16695453">
         <span class="h2">
          Alloimmunization
         </span>
         <span class="headingEndMark">
          —
         </span>
         Alloimmunization (development of antibodies directed at blood cell antigens) accounts for a minority of cases of platelet refractoriness. Exposure to blood cell antigens can occur through prior transfusions, pregnancy, or hematopoietic stem cell (HSC) transplantation (HSCT).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anti-HLA
         </strong>
         – The most common types of epitopes are from the human leukocyte antigen (HLA) system, which are present on platelets, white blood cells (WBCs), and various immune tissues. Antibodies targeting HLA-A and HLA-B epitopes are typically implicated; anti-HLA-C antibodies have been reported as a rare cause of alloimmune refractoriness, but anti-HLA-C are typically not considered a cause of platelet refractoriness [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Pregnancy is the most important risk factor for HLA alloimmunization. In a 2009 study of &gt;8000 blood donors, circulating anti-HLA antibodies were present in approximately 24 percent of previously pregnant female blood donors who had anti-HLA [
         <a href="#rid3">
          3
         </a>
         ]. The rate of anti-HLA increased according to the number of pregnancies, from 1.7 percent with one pregnancy to 32 percent with four or more pregnancies [
         <a href="#rid22">
          22
         </a>
         ]. In contrast, rates of anti-HLA antibodies in previously transfused and nontransfused male donors were 1.7 and 1.0 percent, respectively [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         HLA alloimmunization can also be stimulated by transfusion; the alloimmunization risk is substantially higher if non-leukoreduced units are transfused. Alloantibodies to foreign ABO antigens develop universally during early life as an immune response to the gastrointestinal microbiome. (See
         <a class="medical medical_review" href="/z/d/html/7924.html" rel="external">
          "Red blood cell antigens and antibodies", section on 'ABO antibodies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         HLA alloimmunization does not always cause clinical platelet refractoriness. In the 1997 TRAP trial, which evaluated the role of pre-storage leukoreduction in preventing platelet refractoriness, alloantibodies developed in 17 to 45 percent of participants depending on treatment assignment, but only 10 percent of patients developed refractoriness [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anti-HPA
         </strong>
         – Less commonly seen epitopes in platelet immune refractoriness are human platelet-specific antigens (HPA). Some platelet antigens are universally expressed and do not lead to alloantibody formation, but others are polymorphic; exposure to foreign HPA can lead to alloantibody formation. The most relevant HPA are GPIa, GPIb, GPIIb, GPIIIA, and CD109.12 [
         <a href="#rid4">
          4
         </a>
         ]. In the TRAP trial, antibodies to HPA epitopes developed 6 to 11 percent of the patients [
         <a href="#rid3">
          3
         </a>
         ]. As would be expected, the prevalence of anti-HPA was not altered by pre-storage leukoreduction.
        </p>
        <p>
        </p>
        <p>
         Although platelets express only HLA Class I antigens, HLA Class II antigens present on WBCs may be essential for the development of alloimmunization to HLA Class I antigens. Foreign HLA Class II antigens can be introduced through prior transfusion or during pregnancy [
         <a href="#rid3">
          3,7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H16695481">
         <span class="h1">
          MONITORING AND EVALUATION
         </span>
        </p>
        <p class="headingAnchor" id="H4178748669">
         <span class="h2">
          When to suspect
         </span>
         <span class="headingEndMark">
          —
         </span>
         Refractoriness to platelet transfusion may be suspected in any individual in whom there is failure to have the expected platelet count increase following platelet transfusion. However, before making the diagnosis, it is important to determine the post-transfusion platelet count increment for at least two transfusions. (See
         <a class="local">
          'Post-transfusion platelet count'
         </a>
         below.)
        </p>
        <p>
         Obtaining an immediate post-transfusion platelet count is not required for individuals in whom refractoriness is not suspected.
        </p>
        <p class="headingAnchor" id="H16695488">
         <span class="h2">
          Post-transfusion platelet count
         </span>
         <span class="headingEndMark">
          —
         </span>
         The immediate post-transfusion platelet count increment is used clinically to establish the diagnosis of platelet refractoriness and to help determine the cause  (
         <a class="graphic graphic_algorithm graphicRef135207" href="/z/d/graphic/135207.html" rel="external">
          algorithm 1
         </a>
         ). Generally, this refers to a platelet count obtained 10 minutes to 1 hour after the transfusion is completed.
        </p>
        <p>
         A repeat count is obtained after 24 hours, and the pattern is used to determine the cause of refractoriness. The rationale for obtaining the immediate post-transfusion platelet count and a count at 24 hours is that in non-immune mechanisms, the platelet count initially rises, but platelets are consumed. In contrast, in alloimmune refractoriness, the platelet count never rises  (
         <a class="graphic graphic_figure graphicRef82283" href="/z/d/graphic/82283.html" rel="external">
          figure 2
         </a>
         ). (See
         <a class="local">
          'Determining the cause'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1890460980">
         <span class="h2">
          CCI
         </span>
         <span class="headingEndMark">
          —
         </span>
         The corrected count increment (CCI) is primarily used for research studies to allow comparable assessments of platelet count increment.
        </p>
        <p class="headingAnchor" id="H16695495">
         <span class="h2">
          Determining the cause
         </span>
         <span class="headingEndMark">
          —
         </span>
         The cause of platelet refractoriness determines management. (See
         <a class="local">
          'Management'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         The figure illustrates typical patterns with non-immune and alloimmune refractoriness  (
         <a class="graphic graphic_figure graphicRef82283" href="/z/d/graphic/82283.html" rel="external">
          figure 2
         </a>
         ). The reliability of these patterns for distinguishing between non-immune and alloimmune refractoriness have been questioned [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In non-immune refractoriness, the immediate post-transfusion platelet increment tends to be reasonably high, with a return to the baseline platelet count within 24 hours. This is also referred to as normal platelet recovery with reduced platelet survival.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In alloimmune refractoriness, the immediate post-transfusion platelet generally does not increase (or increases only slightly).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Anti-HLA antibodies
         </strong>
         – The second step in determining refractoriness is to assay for anti-human leukocyte antigen (anti-HLA) alloantibodies. The calculated panel reactive antibody (cPRA) provides a score from 0 to 100 percent (the lower the score, the less reactivity). In one study, the likelihood of identifying crossmatch compatible platelets was greatest in individuals with a cPRA &lt;70 percent [
         <a href="#rid23">
          23
         </a>
         ]. If anti-HLA antibodies are identified in a patient with platelet refractoriness, they can be avoided in subsequent transfusions. (See
         <a class="local">
          'Positive PRA (anti-HLA alloantibodies)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Panel reactive antibody (PRA) testing can be omitted if a non-immune cause is considered likely, such as in a patient with a large platelet count increment immediately after transfusion who is known to have one or more potential causes of non-immune platelet refractoriness (fever/sepsis, splenomegaly, disseminated intravascular coagulation [DIC]).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Methods to detect the presence and specificity of anti-HLA antibodies include lymphocytotoxicity, immunoassays such as enzyme-linked immunosorbent assays (ELISAs), and flow cytometric immunofluorescence testing, depending on the laboratory performing testing [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Anti-HPA antibodies
         </strong>
         – If the screen for anti-HLA antibodies is negative, testing for antibodies to the human platelet antigen system (anti-HPA antibodies) can be performed; use is institution-dependent. In institutions where this is not done, platelet crossmatching can be used.
        </p>
        <p>
        </p>
        <p>
         Not all detectable alloantibodies are clinically significant; HLA antibodies that are capable of activating complement may have a greater likelihood of causing platelet refractoriness. Higher levels of antibody may also be associated with greater risk of refractoriness [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1390546693">
         <span class="h1">
          PREVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The major preventive intervention is to minimize risk factors, especially alloimmunization. Indications for platelet transfusion should be reviewed and unnecessary transfusions avoided. (See
         <a class="medical medical_review" href="/z/d/html/7948.html" rel="external">
          "Indications and hemoglobin thresholds for RBC transfusion in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7918.html" rel="external">
          "Platelet transfusion: Indications, ordering, and associated risks"
         </a>
         .)
        </p>
        <p>
         Platelets express human leukocyte antigen (HLA) class I and ABO antigens on their surface, as well as platelet specific antigens; they do not express HLA class II or Rh antigens. A 2001 guideline from the American Society of Clinical Oncology (ASCO), updated in 2018, endorsed pre-storage leukoreduction for all cellular blood products in individuals with acute myeloid leukemia (AML) receiving chemotherapy, as well as in individuals with other hematologic malignancies [
         <a href="#rid5">
          5,26
         </a>
         ].
        </p>
        <p>
         Major preventive approaches are to use leukoreduced products when possible. Medical conditions that decrease platelet survival should be treated.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Leukoreduction
         </strong>
         – Leukoreduction decreases exposure to HLA Class I antigens on white blood cells. Many countries practice universal pre-storage leukoreduction; in the United States, most cellular products undergo pre-storage leukoreduction. Clinicians caring for patients who may require platelet transfusions should familiarize themselves with local practices and ensure that pre-storage leukoreduction is used for individuals who may require multiple platelet transfusions. Details and other indications are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7939.html" rel="external">
          "Practical aspects of red blood cell transfusion in adults: Storage, processing, modifications, and infusion", section on 'Pre-storage leukoreduction'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The benefit of leukoreduction in reducing alloimmunization was demonstrated in the 1997 TRAP trial, which randomly assigned 530 patients with no detectable preexisting alloantibodies who were receiving induction chemotherapy for AML to receive platelet transfusions prepared in one of four ways, and documented the following incidences of platelet refractoriness during the eight weeks of the trial [
         <a href="#rid3">
          3
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Non-leukoreduced pooled platelets (from whole blood donations) – 16 percent (95% CI, 10 to 23 percent)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ultraviolet B (UVB)-irradiated pooled platelets – 10 percent (6 to 16 percent)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Leukoreduced pooled platelets – 7 percent (4 to 13 percent)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Leukoreduced apheresis platelets – 8 percent (4 to 14 percent)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Rates of refractoriness were higher in females who had ever been pregnant; rates were similar between males and never-pregnant females [
         <a href="#rid3">
          3,6
         </a>
         ]. Rates of functional anti-HLA antibodies (measured in a lymphocyte killing assay) were approximately two-fold higher than rates of refractoriness in all groups.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          ABO matching
         </strong>
         – It has been suggested that ABO matching can reduce the risk of HLA alloimmunization, although data are very limited [
         <a href="#rid27">
          27
         </a>
         ]. ABO matching (with ABO identical or ABO compatible platelets) prevents platelet clearance by pre-formed antibodies in the recipient directed against ABO antigens. Many institutions give priority to patients at highest risk for platelet refractoriness when determining which patients should receive ABO compatible platelets (prioritizing hematopoietic stem cell transplant recipients). In many institutions, low inventory does not allow universal ABO matching. Observational studies have generally found better platelet count increments with transfusion of ABO compatible platelets compared with ABO incompatible platelets [
         <a href="#rid2">
          2,28-34
         </a>
         ]. Rh matching is not a consideration, as platelets do not express Rh antigens.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of other conditions
         </strong>
         – It is prudent to treat any underlying conditions that contribute to decreased platelet survival by non-immune mechanisms. (See
         <a class="local">
          'Management of non-immune refractoriness'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management depends on the underlying cause of platelet refractoriness  (
         <a class="graphic graphic_algorithm graphicRef135207" href="/z/d/graphic/135207.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Factors associated with platelet refractoriness'
         </a>
         above.)
        </p>
        <p>
         For individuals with alloimmunization, avoiding the implicated platelet antigens is most helpful. For those with non-immune mechanisms, the underlying cause of platelet consumption should be addressed.
        </p>
        <p>
         For the most part, immunosuppressive therapies have not proven particularly helpful in treating platelet refractoriness. (See
         <a class="local">
          'Limited role of immunosuppressive therapies'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3950022667">
         <span class="h2">
          Management of alloimmune refractoriness
         </span>
        </p>
        <p class="headingAnchor" id="H149027398">
         <span class="h3">
          Positive PRA (anti-HLA alloantibodies)
         </span>
         <span class="headingEndMark">
          —
         </span>
         The panel reactive antibody (PRA) or calculated PRA (cPRA) is the standard test for anti-human leukocyte antigen (anti-HLA) antibodies. PRA testing was previously performed using a lymphocyte cytotoxicity assay; most modern laboratories screen for HLA antibodies with a flow cytometric method using HLA antigen-coated beads.
        </p>
        <p>
         Patients with clinical refractoriness who have anti-HLA antibodies are transfused with either HLA-matched platelets, HLA antigen-exclusion platelet units, or crossmatched platelet units  (
         <a class="graphic graphic_algorithm graphicRef135207" href="/z/d/graphic/135207.html" rel="external">
          algorithm 1
         </a>
         ). Efficacy is considered comparable, and the decision of which to use is based on availability, inventory, cost, and other factors [
         <a href="#rid4">
          4
         </a>
         ]. HLA-matched platelets are not indicated when the PRA is low (eg, &lt;20 percent).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HLA-matched platelets
         </strong>
         – Once a patient's HLA class I (A and B) type has been determined, platelet units with identical or similar HLA class I antigens can be selected for transfusion. Many apheresis platelet donors who donate regularly are HLA typed by the blood donation center, and information on their HLA type is readily available.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The degree of similarity is referred to as the HLA "match grade" [
         <a href="#rid4">
          4
         </a>
         ]. The better the match, the more likely that the patient will have an adequate increment to transfused platelets. Platelet units with a grade A match (all four HLA A and B antigens identical between donor and recipient) are optimal. However, grade A match units are challenging to find, and it is common to use grade B match units (one antigen out of four is mismatched). Transfusing HLA-matched platelets below grade B match (C or D matches) often results in a poor platelet increment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HLA antigen-exclusion platelets
         </strong>
         – Antigen-negative platelets are not fully HLA-matched, but they lack the antigen(s) thought to be implicated in platelet refractoriness.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Crossmatch-compatible platelets
         </strong>
         – Crossmatch-compatible platelets have been used as a more convenient and less expensive approach than HLA-matched platelets, although in some institutions they may be more expensive. Crossmatch compatible platelets are identified by crossmatching apheresis platelet units with the patient's serum [
         <a href="#rid34">
          34-36
         </a>
         ]. Crossmatching can be performed in a few hours, as opposed to the days it may take to identify HLA-matched platelets [
         <a href="#rid37">
          37
         </a>
         ]. Crossmatching can also benefit patients with uncommon HLA types for whom it would be very difficult to find an HLA-matched donor. Additionally, it avoids exclusion of HLA-mismatched but otherwise compatible donors thereby increasing the number of potentially compatible units. These serologic techniques are typically available through community blood centers with commercially available kits [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         If HLA-compatible platelets are not available (or while they are being tested and procured), ABO-compatible platelets can be used as a means of improving the platelet count increment. However, this is unlikely to be effective for individuals with HLA alloimmune refractoriness. (See
         <a class="medical medical_review" href="/z/d/html/7918.html" rel="external">
          "Platelet transfusion: Indications, ordering, and associated risks", section on 'ABO, Rh, and HLA matching'
         </a>
         .)
        </p>
        <p>
         There are no randomized trials comparing these three approaches; for the most part, crossmatch-compatible platelets, HLA-matched platelets, and antigen-exclusion platelets are thought to provide equivalent efficacy for identifying a compatible platelet unit that can result in a reasonable platelet increment [
         <a href="#rid1">
          1,4
         </a>
         ]. A small retrospective study (354 platelet transfusions in 32 patients) reported corrected count intervals (CCI) &gt;5000/microL with 25 percent with crossmatch compatible units and 30 percent with HLA-matched units, both of which were better than random donor units (CCI &gt;5000/microL with only 12 percent of units) [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         In a study of 50 pediatric patients with beta thalassemia major and platelet transfusion refractoriness following hematopoietic stem cell transplantation, transfusion outcome depended upon both the degree of HLA matching and ABO compatibility, is as follows [
         <a href="#rid40">
          40
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Matched at HLA and ABO compatible: 76 percent successful platelet transfusions
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Matched at HLA and ABO incompatible or mismatched at HLA and ABO compatible: 67 percent successful
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mismatched at HLA and ABO incompatible: 46 percent successful
        </p>
        <p>
        </p>
        <p>
         Several other observational studies have demonstrated that individuals with HLA alloimmune platelet refractoriness generally have a good platelet count response with HLA-matched donor platelets [
         <a href="#rid34">
          34,41,42
         </a>
         ].
        </p>
        <p>
         It is
         <strong>
          mandatory
         </strong>
         that when HLA-matched (or other types of HLA-compatible) platelet transfusions are used, the product
         <strong>
          must
         </strong>
         be irradiated before it is transfused. This is because individuals receiving HLA-matched blood products are at risk for transfusion-associated graft-versus-host disease (TA-GVHD) caused by lymphocytes in the product that recognize the transfusion recipient's tissues (bone marrow, skin, gastrointestinal tract) as foreign and attack them, leading to pancytopenia that is typically fatal. All HLA-matched platelets must be irradiated prior to transfusion to prevent TA-GVHD. (See
         <a class="medical medical_review" href="/z/d/html/7928.html" rel="external">
          "Transfusion-associated graft-versus-host disease", section on 'Partial HLA matching'
         </a>
         .)
        </p>
        <p>
         Alternative computerized matching techniques are now emerging and may further improve the ability of blood banks to provide apheresis platelets for HLA-alloimmunized patients. As an example, the HLAMatchmaker is a software algorithm that predicts HLA compatibility including acceptable mismatched options. This method takes into account matching for highly immunogenic HLA epitopes, HLA matching on a deoxyribonucleic acid (DNA) rather than a serological level, and as well as HLA-C antigens [
         <a href="#rid36">
          36,43-47
         </a>
         ]. A randomized trial comparing HLA-matched platelets identified using HLAMatchmaker versus standard HLA matching found generally similar outcomes between the two [
         <a href="#rid42">
          42
         </a>
         ]. The degree of HLA match correlated with platelet count increment.
        </p>
        <p>
         An immediate post-transfusion count should be obtained to determine the response to these units. It is especially important to monitor response when using antigen-exclusion platelets (because the antibody profile may change) and also relevant with other methods. (See
         <a class="local">
          'Post-transfusion platelet count'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3282825188">
         <span class="h3">
          Positive for anti-HPA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antibodies against human platelet antigen (HPA) are an uncommon cause of platelet refractoriness. Some centers test for anti-HLA and anti-HPA simultaneously and others do the testing sequentially (reserving anti-HPA testing for individuals who do not demonstrate anti-HLA) [
         <a href="#rid1">
          1
         </a>
         ]. Sequential testing is often more cost-effective and more commonly done  (
         <a class="graphic graphic_algorithm graphicRef135207" href="/z/d/graphic/135207.html" rel="external">
          algorithm 1
         </a>
         ). If the institution does not perform anti-HPA testing, platelet crossmatching can be done instead.
        </p>
        <p>
         If anti-HPA antibodies are identified, the relevant HPA antigens can be avoided in future transfusions (eg, using HPA-typed donors or crossmatching). Typically this is restricted to HPA-1a; for other antigens, crossmatching may be needed.
        </p>
        <p class="headingAnchor" id="H2224631814">
         <span class="h3">
          Limited role of immunosuppressive therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immunosuppressive therapies have been used for individuals with alloimmune platelet refractoriness with limited success. We suggest not routinely using intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG), splenectomy, or other immunosuppressive approaches, consistent with other experts, although immunosuppressive therapies (IVIG, off-label
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         or
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         ) may be used in extenuating circumstances.
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         - IVIG, with or without therapeutic apheresis, has been proposed as a strategy for immune modulation, but the results have generally been unimpressive [
         <a href="#rid48">
          48-50
         </a>
         ]. In a randomized trial from 1990 involving 12 patients with platelet refractoriness, those assigned to receive IVIG (400 mg/kg daily for five days) had improved platelet recovery at 1 to 6 hours post-transfusion, while those assigned to placebo did not have any improvement (corrected count interval [CCI] 8413/microL with IVIG versus 1050/microL with placebo; p &lt;0.007) [
         <a href="#rid50">
          50
         </a>
         ]. Neither group had improved platelet counts at 24 hours.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          Rituximab
         </a>
         <strong>
          or
         </strong>
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         – Rituximab and bortezomib have been described as promising in case reports, although further investigation is needed [
         <a href="#rid51">
          51-54
         </a>
         ]. We have not used these agents in platelet refractoriness.
        </p>
        <p>
        </p>
        <p>
         An important role of T cells in alloimmune refractoriness may explain the lack of efficacy of B cell directed therapies [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2389523893">
         <span class="h2">
          Management of non-immune refractoriness
         </span>
         <span class="headingEndMark">
          —
         </span>
         Non-immune refractoriness is managed by treating the underlying cause of increased platelet consumption  (
         <a class="graphic graphic_algorithm graphicRef135207" href="/z/d/graphic/135207.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Non-immune causes'
         </a>
         above.)
        </p>
        <p>
         Examples include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment of infections
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment of underlying causes of DIC
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Discontinuation of any medications that could cause drug-induced thrombocytopenia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Addressing sources of bleeding
        </p>
        <p>
        </p>
        <p>
         It has not been determined whether treatment of fever with an antipyretic agent can improve platelet count increment independent of treating infections.
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          TREATMENT OF BLEEDING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Major bleeding (or minor bleeding expected to progress to major bleeding) requires a coordinated approach, especially in individuals with platelet refractoriness. Urgent involvement of the transfusion medicine service and individuals with expertise in hemostasis is advised.
        </p>
        <p>
         The following may be appropriate:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Platelet transfusions
         </strong>
         – Even if the post-transfusion platelet count increment is low, continued platelet transfusions may be helpful, as transfused platelets may contribute to hemostasis. For individuals with alloimmune refractoriness, the most compatible platelets available can be used. If there is no platelet count increase and no reduction of bleeding, a clinician may determine that further transfusions would not provide any benefit and only confer risks associated with transfusion, and they may decide to discontinue transfusions. (See
         <a class="local">
          'Management of alloimmune refractoriness'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other hemostatic therapies
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Antifibrinolytic therapy
         </strong>
         –
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          Tranexamic acid
         </a>
         or epsilon
         <a class="drug drug_general" data-topicid="8561" href="/z/d/drug information/8561.html" rel="external">
          aminocaproic acid
         </a>
         are commonly used for bleeding, especially bleeding in mucosal sites (nose, oropharynx, urogenital tract), which have increased fibrinolytic activity [
         <a href="#rid56">
          56
         </a>
         ]. However, evidence is lacking to support the use of antifibrinolytic therapy in patients with thrombocytopenia; preliminary results of a randomized trial suggest that tranexamic acid does not reduce the risk of clinically important bleeding [
         <a href="#rid57">
          57
         </a>
         ]. Antifibrinolytic agents are contraindicated in patients with disseminated intravascular coagulation (DIC). (See
         <a class="medical medical_review" href="/z/d/html/1306.html" rel="external">
          "Evaluation and management of disseminated intravascular coagulation (DIC) in adults", section on 'Avoid antifibrinolytic agents and PCCs'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          rFVIIa
         </strong>
         – Recombinant activated factor VII (rFVIIa) is sometimes used off-label in situations with extreme bleeding when other therapies are ineffective. Case reports have described use of rFVIIa in individuals with alloimmune platelet refractoriness [
         <a href="#rid58">
          58
         </a>
         ]. Thrombosis is a risk, even in individuals with thrombocytopenia, although the exact level of risk is challenging to determine. This therapy would only be used in a rare, life-threatening bleeding episode in which platelet transfusions are ineffective. Dosing is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1341.html" rel="external">
          "Recombinant factor VIIa: Administration and adverse effects", section on 'Off-label uses'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1341.html" rel="external">
          "Recombinant factor VIIa: Administration and adverse effects", section on 'General approach to administration'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treat the cause of thrombocytopenia
         </strong>
         – Whenever possible, treatment for the underlying cause of thrombocytopenia should be used, even if it may take time to become effective. For immune thrombocytopenia (ITP), intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG) is generally the fastest means of increasing the platelet count. (See
         <a class="medical medical_review" href="/z/d/html/6677.html" rel="external">
          "Initial treatment of immune thrombocytopenia (ITP) in adults", section on 'Therapies to raise the platelet count'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          TPO-RAs
         </strong>
         – Thrombopoietin receptor agonists (TPO-RAs) can raise the platelet count, but their effect takes several days, which will not treat bleeding urgently. (See
         <a class="medical medical_review" href="/z/d/html/6671.html" rel="external">
          "Clinical applications of thrombopoietic growth factors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Immunosuppressive therapies are rarely helpful and do not act rapidly, but they may be used in exceptional circumstances. (See
         <a class="local">
          'Limited role of immunosuppressive therapies'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2639129338">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/120167.html" rel="external">
          "Society guideline links: Transfusion and patient blood management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8634211">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – Platelet refractoriness is defined as a platelet count increment less than expected after at least two platelet transfusions. Quantitative definitions may be used but should not substitute for clinical judgment. The prevalence varies depending on the patient population. (See
         <a class="local">
          'Definition and prevalence'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Associated conditions
         </strong>
         – Conditions associated with platelet refractoriness are broadly divided into non-immune causes (fever/sepsis, splenomegaly, disseminated intravascular coagulation [DIC]) and alloimmune causes (alloantibodies to platelet antigens); non-immune factors are more common  (
         <a class="graphic graphic_table graphicRef67416" href="/z/d/graphic/67416.html" rel="external">
          table 1
         </a>
         ). Most alloantibodies are directed against human leukocyte antigen (HLA) antigens, typically HLA-A and HLA-B; less commonly, alloantibodies against human platelet antigen (HPA) epitopes may be responsible. Non-immune and alloimmune causes often coexist. (See
         <a class="local">
          'Factors associated with platelet refractoriness'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
         – Platelet refractoriness may be suspected if platelet transfusion does not result in the expected increase in platelet count  (
         <a class="graphic graphic_algorithm graphicRef135207" href="/z/d/graphic/135207.html" rel="external">
          algorithm 1
         </a>
         ). It is important to determine the immediate post-transfusion platelet count (obtained 10 minutes to 1 hour after the transfusion is finished) and the count at 24 hours, for at least two transfusions. A platelet count increase of &lt;10,000/microL(or no increase) on at least two occasions indicates refractoriness. An increase in the immediate post-transfusion count and a fall to baseline by 24 hours is consistent with a non-immune mechanism, while absence of an increase immediately post-transfusion is consistent with an alloimmune mechanism  (
         <a class="graphic graphic_figure graphicRef82283" href="/z/d/graphic/82283.html" rel="external">
          figure 2
         </a>
         ). The corrected count increment (CCI) is generally reserved for research.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention
         </strong>
         – Other than avoiding unnecessary transfusions, pre-storage leukoreduction is the primary means of reducing alloimmunization and platelet refractoriness. Conditions that contribute to platelet consumption should be treated. (See
         <a class="local">
          'Prevention'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management recommendations
         </strong>
         – Management is summarized in the flowchart  (
         <a class="graphic graphic_algorithm graphicRef135207" href="/z/d/graphic/135207.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Alloimmune refractoriness
         </strong>
         – For patients with a component of alloimmune refractoriness (eg, positive panel reactive antibody [PRA]), we suggest using platelets that are HLA-matched, HLA antigen-negative, or crossmatch-compatible (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The choice among these options may be based on cost, availability, inventory, or other factors. For alloimmune refractoriness without anti-HLA antibodies, we check for anti-HPA antibodies and provide antigen-negative platelets. Immunosuppressive therapies do not appear helpful in most cases of alloimmune refractoriness and are generally reserved for extreme cases. (See
         <a class="local">
          'Management of alloimmune refractoriness'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Importance of platelet irradiation
         </strong>
         – When HLA-matched, crossmatched, or antigen avoidance platelet transfusions are used, it is
         <strong>
          mandatory
         </strong>
         that the product be irradiated before it is transfused, to prevent transfusion-associated graft-versus-host disease (TA-GVHD), a fatal complication associated with partially HLA-matched blood components. (See
         <a class="medical medical_review" href="/z/d/html/7928.html" rel="external">
          "Transfusion-associated graft-versus-host disease", section on 'Prevention'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Non-immune refractoriness
         </strong>
         – For individuals with a component of non-immune refractoriness, the underlying cause should be addressed when possible. (See
         <a class="local">
          'Management of non-immune refractoriness'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients with bleeding
         </strong>
         – Individuals with major bleeding (or concern for progression to major bleeding) and thrombocytopenia should receive platelet transfusions with the most compatible platelets available. Other therapies may include an antifibrinolytic agent, other hemostatic therapy, and therapies to improve the platelet count in the longer-term (thrombopoietin receptor agonist [TPO-RA], immunosuppressive therapy). (See
         <a class="local">
          'Treatment of bleeding'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2024357957">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges James D Burner, MD; Ann Secord, MD, CDR, MC, USN Ret; Ana Ortega Lopez, MD; Alyssa Ziman, MD; and Dennis Goldfinger, MD (deceased), all of whom contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Cohn CS. Platelet transfusion refractoriness: how do I diagnose and manage? Hematology Am Soc Hematol Educ Program 2020; 2020:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slichter SJ, Davis K, Enright H, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005; 105:4106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997; 337:1861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forest SK, Hod EA. Management of the Platelet Refractory Patient. Hematol Oncol Clin North Am 2016; 30:665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schiffer CA, Bohlke K, Delaney M, et al. Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2018; 36:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hess JR, Trachtenberg FL, Assmann SF, et al. Clinical and laboratory correlates of platelet alloimmunization and refractoriness in the PLADO trial. Vox Sang 2016; 111:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Legler TJ, Fischer I, Dittmann J, et al. Frequency and causes of refractoriness in multiply transfused patients. Ann Hematol 1997; 74:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol 2008; 142:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brixner V, Bug G, Pohler P, et al. Efficacy of UVC-treated, pathogen-reduced platelets versus untreated platelets: a randomized controlled non-inferiority trial. Haematologica 2021; 106:1086.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lieberman L, Liu Y, Barty R, Heddle NM. Platelet transfusion practice and platelet refractoriness for a cohort of pediatric oncology patients: A single-center study. Pediatr Blood Cancer 2020; 67:e28734.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Belizaire R, Makar RS. Non-Alloimmune Mechanisms of Thrombocytopenia and Refractoriness to Platelet Transfusion. Transfus Med Rev 2020; 34:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bishop JF, McGrath K, Wolf MM, et al. Clinical factors influencing the efficacy of pooled platelet transfusions. Blood 1988; 71:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Böck M, Muggenthaler KH, Schmidt U, Heim MU. Influence of antibiotics on posttransfusion platelet increment. Transfusion 1996; 36:952.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stéphan F, Cheffi MA, Kaplan C, et al. Autoantibodies against platelet glycoproteins in critically ill patients with thrombocytopenia. Am J Med 2000; 108:554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bogdonoff DL, Williams ME, Stone DJ. Thrombocytopenia in the critically ill patient. J Crit Care 1990; 5:186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           George MR, Herman JH, Holdbrook T, et al. Platelet refractoriness in acquired hemophagocytic syndrome. Transfusion 2011; 51:2319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aster RH. Pooling of platelets in the spleen: role in the pathogenesis of "hypersplenic" thrombocytopenia. J Clin Invest 1966; 45:645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ventura GJ, Hester JP, Dixon DO, et al. Analysis of risk factors for fatal hemorrhage during induction therapy of patients with acute promyelocytic leukemia. Hematol Pathol 1989; 3:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones RJ, Lee KS, Beschorner WE, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44:778.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rio B, Andreu G, Nicod A, et al. Thrombocytopenia in venocclusive disease after bone marrow transplantation or chemotherapy. Blood 1986; 67:1773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saito S, Ota S, Seshimo H, et al. Platelet transfusion refractoriness caused by a mismatch in HLA-C antigens. Transfusion 2002; 42:302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Triulzi DJ, Kleinman S, Kakaiya RM, et al. The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy. Transfusion 2009; 49:1825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pandey S, Rosenbaum E, Cottler-Fox M, Harville TO. Percent cPRA (Calculated Panel Reactive Antibody) Value Predicts Percent of Positive Platelet Crossmatches. Ann Clin Lab Sci 2017; 47:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kopko PM, Warner P, Kresie L, Pancoska C. Methods for the selection of platelet products for alloimmune-refractory patients. Transfusion 2015; 55:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sullivan JC, Peña JR. Use of Human Leukocyte Antigen (HLA)-Incompatible Platelet Units in HLA Platelet-Refractory Patients With Limited Number of or Low-Level HLA Donor-Specific Antibodies Results in Permissive Transfusions. Arch Pathol Lab Med 2022; 146:1243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19:1519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cardillo A, Heal JM, Henrichs K, et al. Reducing the Need for HLA-Matched Platelet Transfusion. N Engl J Med 2021; 384:2451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lozano M, Cid J. The clinical implications of platelet transfusions associated with ABO or Rh(D) incompatibility. Transfus Med Rev 2003; 17:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Josephson CD, Mullis NC, Van Demark C, Hillyer CD. Significant numbers of apheresis-derived group O platelet units have "high-titer" anti-A/A,B: implications for transfusion policy. Transfusion 2004; 44:805.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Julmy F, Ammann RA, Taleghani BM, et al. Transfusion efficacy of ABO major-mismatched platelets (PLTs) in children is inferior to that of ABO-identical PLTs. Transfusion 2009; 49:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaufman RM. Platelet ABO matters. Transfusion 2009; 49:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Triulzi DJ, Assmann SF, Strauss RG, et al. The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia. Blood 2012; 119:5553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aster RH. Effect of anticoagulant and ABO incompatibility on recovery of transfused human platelets. Blood 1965; 26:732.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heal JM, Blumberg N, Masel D. An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients. Blood 1987; 70:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petz LD, Garratty G, Calhoun L, et al. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity. Transfusion 2000; 40:1446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vassallo RR, Fung M, Rebulla P, et al. Utility of cross-matched platelet transfusions in patients with hypoproliferative thrombocytopenia: a systematic review. Transfusion 2014; 54:1180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sacher RA, Kickler TS, Schiffer CA, et al. Management of patients refractory to platelet transfusion. Arch Pathol Lab Med 2003; 127:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rebulla P, Morelati F, Revelli N, et al. Outcomes of an automated procedure for the selection of effective platelets for patients refractory to random donors based on cross-matching locally available platelet products. Br J Haematol 2004; 125:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rioux-Massé B, Cohn C, Lindgren B, et al. Utilization of cross-matched or HLA-matched platelets for patients refractory to platelet transfusion. Transfusion 2014; 54:3080.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marktel S, Napolitano S, Zino E, et al. Platelet transfusion refractoriness in highly immunized beta thalassemia children undergoing stem cell transplantation. Pediatr Transplant 2010; 14:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levin MD, Kappers-Klunne M, Sintnicolaas K, et al. The value of alloantibody detection in predicting response to HLA-matched platelet transfusions. Br J Haematol 2004; 124:244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marsh JC, Stanworth SJ, Pankhurst LA, et al. An epitope-based approach of HLA-matched platelets for transfusion: a noninferiority crossover randomized trial. Blood 2021; 137:310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nambiar A, Duquesnoy RJ, Adams S, et al. HLAMatchmaker-driven analysis of responses to HLA-typed platelet transfusions in alloimmunized thrombocytopenic patients. Blood 2006; 107:1680.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duquesnoy RJ. Structural epitope matching for HLA-alloimmunized thrombocytopenic patients: a new strategy to provide more effective platelet transfusion support? Transfusion 2008; 48:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brooks EG, MacPherson BR, Fung MK. Validation of HLAMatchmaker algorithm in identifying acceptable HLA mismatches for thrombocytopenic patients refractory to platelet transfusions. Transfusion 2008; 48:2159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pai SC, Lo SC, Lin Tsai SJ, et al. Epitope-based matching for HLA-alloimmunized platelet refractoriness in patients with hematologic diseases. Transfusion 2010; 50:2318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bub CB, Gonçalez AC, Barjas-Castro ML, et al. The use of a potential novel tool in virtual crossmatching for platelet transfusion in platelet refractoriness. Vox Sang 2016; 110:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeigler ZR, Shadduck RK, Rosenfeld CS, et al. Intravenous gamma globulin decreases platelet-associated IgG and improves transfusion responses in platelet refractory states. Am J Hematol 1991; 38:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schiffer CA, Hogge DE, Aisner J, et al. High-dose intravenous gammaglobulin in alloimmunized platelet transfusion recipients. Blood 1984; 64:937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kickler T, Braine HG, Piantadosi S, et al. A randomized, placebo-controlled trial of intravenous gammaglobulin in alloimmunized thrombocytopenic patients. Blood 1990; 75:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu W, Wu D, Hu T, Ye B. Efficiency of treatment with rituximab in platelet transfusion refractoriness: a study of 7 cases. Int J Clin Exp Med 2015; 8:14080.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cid J, Magnano L, Acosta M, et al. Rituximab, plasma exchange and intravenous immunoglobulins as a new treatment strategy for severe HLA alloimmune platelet refractoriness. Platelets 2015; 26:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu QH, Shen YP, Ye BD, Zhou YH. Successful use of rituximab in platelet transfusion refractoriness in a multi-transfused patient with myelodysplastic syndrome. Platelets 2015; 26:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miki H, Ozaki S, Tanaka O, et al. Marked improvement of platelet transfusion refractoriness after bortezomib therapy in multiple myeloma. Int J Hematol 2009; 89:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manis JP, Silberstein LE. Platelet refractoriness: it's not the B-all and end-all. Blood 2016; 127:1740.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalmadi S, Tiu R, Lowe C, et al. Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. Cancer 2006; 107:136.
          </a>
         </li>
         <li class="breakAll">
          https://ash.confex.com/ash/2020/webprogram/Paper138920.html (Accessed on March 01, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heuer L, Blumenberg D. Management of bleeding in a multi-transfused patient with positive HLA class I alloantibodies and thrombocytopenia associated with platelet dysfunction refractory to transfusion of cross-matched platelets. Blood Coagul Fibrinolysis 2005; 16:287.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7922 Version 33.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33275694" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Platelet transfusion refractoriness: how do I diagnose and manage?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15692069" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9417523" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27113003" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Management of the Platelet Refractory Patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29182495" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27185561" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Clinical and laboratory correlates of platelet alloimmunization and refractoriness in the PLADO trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9174547" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Frequency and causes of refractoriness in multiply transfused patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18510692" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Platelet transfusion refractoriness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33538149" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Efficacy of UVC-treated, pathogen-reduced platelets versus untreated platelets: a randomized controlled non-inferiority trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32975362" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Platelet transfusion practice and platelet refractoriness for a cohort of pediatric oncology patients: A single-center study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33129606" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Non-Alloimmune Mechanisms of Thrombocytopenia and Refractoriness to Platelet Transfusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3337903" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Clinical factors influencing the efficacy of pooled platelet transfusions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8937402" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Influence of antibiotics on posttransfusion platelet increment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10806284" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Autoantibodies against platelet glycoproteins in critically ill patients with thrombocytopenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Thrombocytopenia in the critically ill patient
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21599673" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Platelet refractoriness in acquired hemophagocytic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5327481" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Pooling of platelets in the spleen: role in the pathogenesis of "hypersplenic" thrombocytopenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2745357" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Analysis of risk factors for fatal hemorrhage during induction therapy of patients with acute promyelocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3321587" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Venoocclusive disease of the liver following bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3518836" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Thrombocytopenia in venocclusive disease after bone marrow transplantation or chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11961234" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Platelet transfusion refractoriness caused by a mismatch in HLA-C antigens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19453983" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28667033" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Percent cPRA (Calculated Panel Reactive Antibody) Value Predicts Percent of Positive Platelet Crossmatches.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25393955" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Methods for the selection of platelet products for alloimmune-refractory patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35171984" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Use of Human Leukocyte Antigen (HLA)-Incompatible Platelet Units in HLA Platelet-Refractory Patients With Limited Number of or Low-Level HLA Donor-Specific Antibodies Results in Permissive Transfusions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11230498" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34161713" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Reducing the Need for HLA-Matched Platelet Transfusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12522772" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The clinical implications of platelet transfusions associated with ABO or Rh(D) incompatibility.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15157243" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Significant numbers of apheresis-derived group O platelet units have "high-titer" anti-A/A,B: implications for transfusion policy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18774963" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Transfusion efficacy of ABO major-mismatched platelets (PLTs) in children is inferior to that of ABO-identical PLTs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19140809" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Platelet ABO matters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22496156" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5844146" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Effect of anticoagulant and ABO incompatibility on recovery of transfused human platelets.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3474041" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11134563" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24032995" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Utility of cross-matched platelet transfusions in patients with hypoproliferative thrombocytopenia: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12683867" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Management of patients refractory to platelet transfusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15015974" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Outcomes of an automated procedure for the selection of effective platelets for patients refractory to random donors based on cross-matching locally available platelet products.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24916382" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Utilization of cross-matched or HLA-matched platelets for patients refractory to platelet transfusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20070557" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Platelet transfusion refractoriness in highly immunized beta thalassemia children undergoing stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14687037" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : The value of alloantibody detection in predicting response to HLA-matched platelet transfusions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33475737" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : An epitope-based approach of HLA-matched platelets for transfusion: a noninferiority crossover randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16269623" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : HLAMatchmaker-driven analysis of responses to HLA-typed platelet transfusions in alloimmunized thrombocytopenic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18005328" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Structural epitope matching for HLA-alloimmunized thrombocytopenic patients: a new strategy to provide more effective platelet transfusion support?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18631168" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Validation of HLAMatchmaker algorithm in identifying acceptable HLA mismatches for thrombocytopenic patients refractory to platelet transfusions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20497513" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Epitope-based matching for HLA-alloimmunized platelet refractoriness in patients with hematologic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26274830" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : The use of a potential novel tool in virtual crossmatching for platelet transfusion in platelet refractoriness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1716849" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Intravenous gamma globulin decreases platelet-associated IgG and improves transfusion responses in platelet refractory states.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6592011" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : High-dose intravenous gammaglobulin in alloimmunized platelet transfusion recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1688499" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : A randomized, placebo-controlled trial of intravenous gammaglobulin in alloimmunized thrombocytopenic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26550372" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Efficiency of treatment with rituximab in platelet transfusion refractoriness: a study of 7 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24867634" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Rituximab, plasma exchange and intravenous immunoglobulins as a new treatment strategy for severe HLA alloimmune platelet refractoriness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23634876" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Successful use of rituximab in platelet transfusion refractoriness in a multi-transfused patient with myelodysplastic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19225725" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Marked improvement of platelet transfusion refractoriness after bortezomib therapy in multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27056995" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Platelet refractoriness: it's not the B-all and end-all.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16708357" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16708357" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15870549" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Management of bleeding in a multi-transfused patient with positive HLA class I alloantibodies and thrombocytopenia associated with platelet dysfunction refractory to transfusion of cross-matched platelets.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
